Heart failure research is a most active area of research in academic, industrial and government-sponsored research and receives intense clinical attention. The recent recognition that inflammation is a risk factor and prognostic factor for heart disease has laid ground for preventive medicine and even anti-infective strategies in prevention and treatment of heart failure.
Heart failure research is a most active area of research in academic, industrial and government-sponsored research and receives intense clinical attention. The recent recognition that inflammation is a risk factor and prognostic factor for heart disease has laid ground for preventive medicine and even anti-infective strategies in prevention and treatment of heart failure.Hinweis: Dieser Artikel kann nur an eine deutsche Lieferadresse ausgeliefert werden.
Die Herstellerinformationen sind derzeit nicht verfügbar.
Autorenporträt
Giora Feuerstein, DuPont Pharmaceuticals Company, Wilmington, DE, USA / Peter Libby, Brigham and Women's Hospital, Boston, MA, USA / Douglas L. Mann, Winters Center for Heart Failure Research, Houston, TX, USA
Inhaltsangabe
Inflammation - a new frontier in cardiac disease and therapeutics.- Pathological aspects and inflammation biomarkers in cardiac diseases.- A biomarker of inflammation in cardiovascular diseases.- Inflammation and coronary artery disease.- Inflammatory cells and their metalloproteinases in cardiac diseases.- The role of matrix metalloproteinases in LV remodeling following myocardial infarction.- Matrix metalloproteinases in heart failure: evidence from experimental models.- Inflammatory cytokines in cardiac diseases.- The clinical experience with anti-cytokine therapy in heart failure.- The role of IL-6 and related cytokines in myocardial remodeling and inflammation - implication for cardiac hypertrophy and heart failure.- Toll-like receptors and the cardiovascular system.- The role of IL-6 in experimental and clinical heart failure.- Oxygen and nitrogen reactive radicals in cardiac inflammation and disease.- Myocardial nitric oxide in cardiac remodeling.- Identification and role of inflammatory oxygen free radicals in cardiac ischemia and reperfusion injury.- The immune and complement system and cardiac diseases.- Immune-mediated myocarditis and interleukin-10.- Immunomodulation in heart failure: experimental models.- The role of complement in myocardial inflammation and reperfusion injury.- Inflammatory signaling pathways in cardiac diseases.- The role of immune and inflammatory cytokines in ischemic preconditioning of the heart - identification of novel cardiac cell survival signaling programs.- Stress-activated signals and their role in myocardial ischemia.- p38 MAPK in cardiac remodeling and failure: cytokine signaling and beyond.- Inflammation and myocarditis.- Inflammation and myocarditis.- The inflammatory process in experimental myocarditis.- Nuclearfactors in cardiac disease.- Peroxisome proliferator activated receptors, inflammation, the vasculature and the heart.- Chemokines and cardiac diseases.- Role of chemokines in the pathogenesis of congestive heart failure.- Neurohormonal mediators and cardiac inflammation.- The role of endothelin-1 in myocardial inflammation and fibrosis.- Cyclooxygenases and cardiac diseases.- Cyclo-oxygenase-2 and myocardial ischemia.- Inflammation and arrhythmias.- Inflammation as a cause and consequence of atrial fibrillation.- Summary: Immune and inflammatory modulators as potential therapeutic targets for cardiac diseases.
Inflammation - a new frontier in cardiac disease and therapeutics.- Pathological aspects and inflammation biomarkers in cardiac diseases.- A biomarker of inflammation in cardiovascular diseases.- Inflammation and coronary artery disease.- Inflammatory cells and their metalloproteinases in cardiac diseases.- The role of matrix metalloproteinases in LV remodeling following myocardial infarction.- Matrix metalloproteinases in heart failure: evidence from experimental models.- Inflammatory cytokines in cardiac diseases.- The clinical experience with anti-cytokine therapy in heart failure.- The role of IL-6 and related cytokines in myocardial remodeling and inflammation - implication for cardiac hypertrophy and heart failure.- Toll-like receptors and the cardiovascular system.- The role of IL-6 in experimental and clinical heart failure.- Oxygen and nitrogen reactive radicals in cardiac inflammation and disease.- Myocardial nitric oxide in cardiac remodeling.- Identification and role of inflammatory oxygen free radicals in cardiac ischemia and reperfusion injury.- The immune and complement system and cardiac diseases.- Immune-mediated myocarditis and interleukin-10.- Immunomodulation in heart failure: experimental models.- The role of complement in myocardial inflammation and reperfusion injury.- Inflammatory signaling pathways in cardiac diseases.- The role of immune and inflammatory cytokines in ischemic preconditioning of the heart - identification of novel cardiac cell survival signaling programs.- Stress-activated signals and their role in myocardial ischemia.- p38 MAPK in cardiac remodeling and failure: cytokine signaling and beyond.- Inflammation and myocarditis.- Inflammation and myocarditis.- The inflammatory process in experimental myocarditis.- Nuclearfactors in cardiac disease.- Peroxisome proliferator activated receptors, inflammation, the vasculature and the heart.- Chemokines and cardiac diseases.- Role of chemokines in the pathogenesis of congestive heart failure.- Neurohormonal mediators and cardiac inflammation.- The role of endothelin-1 in myocardial inflammation and fibrosis.- Cyclooxygenases and cardiac diseases.- Cyclo-oxygenase-2 and myocardial ischemia.- Inflammation and arrhythmias.- Inflammation as a cause and consequence of atrial fibrillation.- Summary: Immune and inflammatory modulators as potential therapeutic targets for cardiac diseases.
Es gelten unsere Allgemeinen Geschäftsbedingungen: www.buecher.de/agb
Impressum
www.buecher.de ist ein Internetauftritt der buecher.de internetstores GmbH
Geschäftsführung: Monica Sawhney | Roland Kölbl | Günter Hilger
Sitz der Gesellschaft: Batheyer Straße 115 - 117, 58099 Hagen
Postanschrift: Bürgermeister-Wegele-Str. 12, 86167 Augsburg
Amtsgericht Hagen HRB 13257
Steuernummer: 321/5800/1497
USt-IdNr: DE450055826
